Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tapentadol

Tapentadol Reactions 1704, p355 - 2 Jun 2018 Skin allergy: case report In a study, a patient [age and sex not stated] was described, who developed skin allergy during treatment with tapentadol [TAPAL-ER 50; route not stated] for pain control. The patient, who had locally advanced squamous cell carcinoma, was receiving chemoradiation therapy with cisplatin. The patient was enrolled in group A and started receiving tapentadol 50mg twice daily for pain control. Subsequently, the patient developed skin allergy [duration of treatment to reaction onset and outcome not stated]. Author comment: "1 patient showed skin allergy with good pain control". Narayanasamy R. To assess the pain control and tolerance to drug induced emesis in oral and neck carcinoma patients undergoing chemoradiation treated for pain relief with tapentadol (TAPAL -ER 50) vs. tramadol plus paracetamol with and without anti-emetic support. Annals of Oncology 29 (Suppl. 3): iii29 (plus poster) abstr. 130P, Mar 2018. Available from: URL: https://doi.org/10.1093/annonc/ mdy047.077 [abstract] - India 803323164 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Tapentadol

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Tapentadol

Abstract

Reactions 1704, p355 - 2 Jun 2018 Skin allergy: case report In a study, a patient [age and sex not stated] was described, who developed skin allergy during treatment with tapentadol [TAPAL-ER 50; route not stated] for pain control. The patient, who had locally advanced squamous cell carcinoma, was receiving chemoradiation therapy with cisplatin. The patient was enrolled in group A and started receiving tapentadol 50mg twice daily for pain control. Subsequently, the patient developed skin...
Loading next page...
 
/lp/springer_journal/tapentadol-MlfvwF3481
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46998-x
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p355 - 2 Jun 2018 Skin allergy: case report In a study, a patient [age and sex not stated] was described, who developed skin allergy during treatment with tapentadol [TAPAL-ER 50; route not stated] for pain control. The patient, who had locally advanced squamous cell carcinoma, was receiving chemoradiation therapy with cisplatin. The patient was enrolled in group A and started receiving tapentadol 50mg twice daily for pain control. Subsequently, the patient developed skin allergy [duration of treatment to reaction onset and outcome not stated]. Author comment: "1 patient showed skin allergy with good pain control". Narayanasamy R. To assess the pain control and tolerance to drug induced emesis in oral and neck carcinoma patients undergoing chemoradiation treated for pain relief with tapentadol (TAPAL -ER 50) vs. tramadol plus paracetamol with and without anti-emetic support. Annals of Oncology 29 (Suppl. 3): iii29 (plus poster) abstr. 130P, Mar 2018. Available from: URL: https://doi.org/10.1093/annonc/ mdy047.077 [abstract] - India 803323164 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References